Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Targacept said the Phase 2 proof of concept trial evaluating TC-5619 as a treatment for adults with attention deficit/hyperactivity disorder (ADHD) failed to meet the primary efficacy outcome measure.
Subscribe to our email newsletter
The primary endpoint of the trial was defined as change from baseline on the Conners’ Adult ADHD Rating Scale-Investigator Rated Total ADHD Symptoms score (CAARS-INV) after four, eight and 12 weeks of dosing, as compared to placebo.
The trial also included a number of assessments as secondary efficacy outcome measures, and results across all of these assessments indicated that TC-5619 had activity in the patient population.
For secondary efficacy outcome measures, TC-5619 outperformed placebo with statistical significance approximately seven times more often than placebo outperformed TC-5619 by the same standard.
TC-5619 was generally well tolerated in the trial, without any serious adverse events.
The double blind, placebo controlled, forced titration Phase 2 trial was conducted at 17 sites in the US.
The trial involved 135 non-tobacco using patients, age 18 to 65, meeting DSM-IV criteria for ADHD, who were randomised to receive either TC-5619 or placebo for 12 weeks.
TC-5619, a highly selective alpha7 neuronal nicotinic receptor modulator, is subject to license by Targacept’s strategic partner AstraZeneca.